Actively Recruiting
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Led by Chinese Pulmonary Vascular Disease Research Group · Updated on 2023-12-20
200
Participants Needed
1
Research Sites
1510 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
CONDITIONS
Official Title
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with Takayasu arteritis with pulmonary artery involvement
You will not qualify if you...
- Patients with pulmonary artery stenosis caused by chronic thromboembolic pulmonary hypertension (CTEPH), fibrosing mediastinitis, or congenital pulmonary artery stenosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China, 100000
Actively Recruiting
Research Team
Z
Zhihong Liu, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here